Chikungunya Virus: qRT-PCR Detection and Clinical Overview

CHIKV is an enveloped, single-stranded positive-sense RNA virus approximately 70 nm in diameter.

Its envelope contains E1 and E2 glycoproteins, which are essential for host cell entry and viral fusion.

Three major genotypes have been identified: West African (WAf), East/Central/South African (ECSA), and Asian lineage, with ECSA strains often associated with higher virulence.

CHIKV is primarily transmitted by Aedes mosquitoes, particularly Aedes aegypti and Aedes albopictus.

These mosquitoes are most active during daytime, especially shortly after sunrise and before sunset.

The virus is maintained in a human–mosquito–human transmission cycle, with humans serving as the primary amplification hosts, while non-human primates act as reservoir hosts in sylvatic cycles.

Following a mosquito bite, CHIKV enters the skin and infects host cells via interaction between the viral E2 protein and the MXRA8 receptor.

The virus replicates initially in local lymph nodes, then enters the bloodstream, causing viremia and systemic dissemination.

Target tissues include liver, spleen, muscles, and joints, leading to both direct cellular damage and immune-mediated inflammation.

Immune complex deposition contributes to synovitis and tendon inflammation, which underlies chronic joint symptoms.

Acute phase (2–12 days incubation): Sudden high fever (>39°C), severe symmetrical joint pain (hands, wrists, ankles, knees), and maculopapular rash.

Subacute phase (within 3 weeks): Persistent joint pain, fatigue, and possible Raynaud-like symptoms.

Chronic phase (>3 months): Up to 40–80% of patients develop chronic arthritis or tenosynovitis, sometimes resembling rheumatoid arthritis.

Molecular detection: qRT-PCR is the gold standard during the acute phase (days 1–7), with sensitivity exceeding 95% for detecting viral RNA in blood or joint fluid.

Serology: IgM antibodies can be detected after day 4 using ELISA, indicating recent infection; IgG seroconversion confirms infection during recovery.

Virus isolation: Performed using mosquito cell lines (e.g., C6/36), mainly for research purposes.

Differential diagnosis: Distinguished from dengue (more bleeding and thrombocytopenia) and Zika virus (milder joint pain but risk of congenital defects).

Virus inactivation: Heat treatment at 56°C for 30 minutes or UV exposure can inactivate the virus. Chemical agents such as 70% ethanol and sodium hypochlorite are also effective.

Vector control: Eliminating standing water, using Wolbachia-infected mosquitoes, and reducing mosquito breeding sites are key strategies.

Personal protection: Use insect repellents, wear protective clothing, and minimize exposure during peak mosquito activity hours.

Currently, there are no specific antiviral treatments for CHIKV infection.

Management focuses on symptomatic relief, including the use of NSAIDs (e.g., naproxen) during the acute phase.

Paracetamol is recommended for fever control, while ibuprofen should be avoided until dengue is excluded.

Chronic joint symptoms may require immunomodulatory therapy such as hydroxychloroquine or methotrexate.

Severe complications (e.g., encephalitis, myocarditis) require supportive care and, in some cases, corticosteroids.